PBA
ROIV icon

Paradigm Biocapital Advisors’s Roivant Sciences ROIV Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,081,767
Closed -$12.6M – 34
2023
Q3 		$12.6M Buy
+1,081,767
New +$12.2M 0.86% 26

Other funds holding ROIV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Paradigm Biocapital Advisors's ROIV Position: Q4 2023 in Review

Paradigm Biocapital Advisors sold out of Roivant Sciences (ROIV) in Q4 2023, closing a stake of 1,081,767 shares — an estimated $12.6M sold.

Paradigm Biocapital Advisors first reported a position in ROIV in Q3 2023 and held it in 1 quarter. The position peaked at $12.6M in Q3 2023. 224 funds tracked by Wall St. Rank hold ROIV as of Q4 2023.

  • Paradigm Biocapital Advisors reported no remaining Roivant Sciences position as of Q4 2023 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 1,081,767 Roivant Sciences shares in Q4 2023, an estimated $12.6M.
  • Paradigm Biocapital Advisors first reported a position in Roivant Sciences in Q3 2023 and held it in 1 quarter.
  • Paradigm Biocapital Advisors's Roivant Sciences position peaked at $12.6M in Q3 2023.
  • 224 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2023.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.